Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating on January 31.Maximize Your ...

The US Food and Drug Administration has approved suzetrigine (Journavx) 50 mg oral tablets, a first-in-class non-opioid ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved in pain signaling.

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non ...

H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.

The Food and Drug Administration (FDA) is hoping a newly approved non-opioid pain medication could help save lives. Dr.

While it's next to impossible to know how many opioids entered the state illegally in 2023, we do know that just under 1.7 ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...